相关实验视频
Updated: Jun 30, 2025
06:08
A Novel Method: Super-selective Adrenal Venous Sampling
Published on: September 15, 2017
23.4K
针对原发性高阿尔多斯特隆症的不同医学治疗方法的比较:系统性审查和网络元分析
Wen-Yu Ho1,2, Ching-Chung Hsiao2,3, Ping-Hsun Wu4
1Department of Nephrology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Therapeutic advances in chronic disease
|March 21, 2024
概括
矿物质皮质类受体抗剂 (MRA) 和上皮道 (ENaC) 抑制剂在原发性高阿尔多斯特症中对血压和具有类似的影响. 斯皮罗诺拉克的妇产不适的风险比eplerenone更高.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 原发性高阿尔多斯特症治疗的疗效和副作用缺乏系统研究.
- 矿物质皮质类受体抗剂 (MRA) 和上皮道 (ENaC) 抑制剂是关键的治疗方法.
研究的目的:
- 使用网络元分析 (NMA) 来比较不同MRA和ENaC抑制剂的疗效和安全性.
- 评估对血压,血清和不良事件的影响.
主要方法:
- 5个RCT (392名参与者) 的系统性审查和频率的NMA.
- 在PubMed,MEDLINE,Cochrane图书馆,EMBASE搜索到2023年6月之前的试验.
- 主要结局:血压,血清,主要心血管不良事件. 二次结局:高胆血症,妇产不良.
主要成果:
- 埃普莱伦,埃萨克塞伦和阿米洛里德显示出与螺旋诺拉克顿相比,可以比较的系统性血压降低.
- 埃普莱伦对透缩血压和血清度校正的影响不那么明显,而不是螺旋.
- 与eplerenone相比,斯皮罗诺拉克的妇产不良风险明显更高.
结论:
- MRA可能对血压和的影响有边际差异,证据可靠性非常低.
- 进一步的研究至关重要,以确定MRA的疗效,特别是死亡率和心血管结果.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
428
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
428
01:25Antihypertensive Drugs: Direct Renin Inhibitors
621
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
621
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
534
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
534
01:33Hormonal Regulation
33.1K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
33.1K
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
806
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
806
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
726
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
726